ADA Standards of Medical Care 2024: Algorithm for intensifying to injectable therapies
ADA Standards of Medical Care in Diabetes 2024: Algorithm for intensifying to injectable therapies (Poster)
Treatment algorithm of the 2024 American Diabetes Association (ADA) Standards of Medical Care in Diabetes referencing Figure 9.4 on selecting injectable therapy for patients with Type 2 Diabetes.
Search the Exchange
The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products. It provides evidence-based information on a variety of topics important to patient care. All information is for educational purposes only and is not intended to promote any products.
Find more information
Find product information
Explore our portfolio of products for treating diabetes, including prescribing information, safety data sheets, and storage and stability information.
Continuing education
Explore accredited diabetes education opportunities supported by Novo Nordisk and provided by third-party organizations.
The purpose of this site is to provide relevant medical and scientific information about Novo Nordisk products and areas of therapeutic interest. Information about investigational products or investigational uses of approved products neither implies FDA approval for these products or uses, nor establishes the safety or efficacy of these products or uses. There is no guarantee that any investigational product or investigational use will receive FDA approval or become commercially available in the United States. Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling.
This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only. Any products referenced on this site may have different labelling in different countries.
